Fig. 5: Combination of BV with ALKi is more effective than single agent therapy for eIMS. | British Journal of Cancer

Fig. 5: Combination of BV with ALKi is more effective than single agent therapy for eIMS.

From: CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

Fig. 5

Tumour growth, PPTC objective response and Kaplan–Meier survival curves for a, b diagnosis or c, d relapse eIMS xenografts treated with BV (twice weekly for six weeks IV, indicated by black vertical lines), crizotinib (daily for 28 days PO, indicated by horizontal green line) or combination, and e, f diagnosis or g, h relapse eIMS xenografts treated with BV (twice weekly for six weeks IV, indicated by black vertical lines), ceritinib (daily for 28 days PO, indicated by horizontal green line) or combination. Vehicle-control groups are three mice, treatment groups are four mice. *: Comparison of treatment group to vehicle-control group. #: Comparison of combination treatment group to 1 mg/kg BV treatment group. γ: Comparison of combination treatment group to ALKi treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001 (Mantel–Cox Test). Vehicle control and single agent ALKi groups for the diagnosis xenografts are the same as presented in the combination studies in Fig. 4.

Back to article page